| Skip navigation | ||
![]() |
![]() | ![]() |
|
|
||
Primary myelofibrosis is a disorder of the bone marrow, in which the marrow is replaced by fibrous (scar) tissue.
The cause of primary myelofibrosis is unknown. Scarring of the bone marrow causes blood to form in abnormal sites, such as the liver and spleen. This causes swelling of these organs.
There are no known risk factors.
The disorder usually develops slowly in people over age 50.
Physical examination shows spleen swelling. Later in the disease, it may also show an enlarged liver.
Tests that may be done include:
An examination of the blood shows teardrop-shaped red blood cells. Bone marrow biopsy may be done to rule out other causes of the symptoms.
There is no specific treatment for primary myelofibrosis. The goal of treatment is to relieve symptoms. Treatment may involve:
In young people, bone marrow transplants appear to improve the outlook.
This disorder causes slowly worsening bone marrow failure with severe anemia. Low platelet count leads to easy bleeding, and spleen swelling may slowly get worse.
The average survival of people with primary myelofibrosis is about 5 years. However, many people survive for decades.
Call for an appointment with your health care provider if symptoms of this disorder develop. Uncontrolled bleeding, shortness of breath, jaundice, and confusion that gets worse require urgent or emergency care.
There is no known prevention.
Myelofibrosis; Idiopathic myelofibrosis; Myeloid metaplasia; Agnogenic myeloid metaplasia
Hoffman R, Benz Jr. EJ, Shattil SJ, et al. Hematology: Basic Principles and Practice. 4th ed. Philladelphia, Pa: Churchill Livingston; 2005.
McPherson RA and Pincus MR. Henry's Clinical Diagnosis and Management by Laboratory Methods. 21st ed. Philadelphia, Pa: WB Saunders; 2007:561-62.
Updated by: David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; and James R. Mason, MD, Oncologist, Director, Blood and Marrow Transplantation Program and Stem Cell Processing Lab, Scripps Clinic, Torrey Pines, California. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.
|
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch). |

| Home | Health Topics | Drugs & Supplements | Encyclopedia | Dictionary | News | Directories | Other Resources | |
| Disclaimers | Copyright | Privacy | Accessibility | Quality Guidelines U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health | Department of Health & Human Services |
Page last updated: 29 October 2009 |